IQVIA Holdings: Strong Performance and Growth Potential Justify Buy Rating

Analyst Tejas Savant of Morgan Stanley maintained a Buy rating on IQVIA Holdings (IQV – Research Report), reducing the price target to $185.00.

Tejas Savant has given his Buy rating due to a combination of factors that highlight IQVIA Holdings’ strong performance and potential for growth. The company’s revenue for the first quarter of 2025 exceeded expectations, driven by robust results in the Research & Development Solutions (R&DS) and Technology & Analytics Solutions (TAS) segments. Despite a decline in the Business-to-Business (B2B) segment, which was anticipated due to pharmaceutical headwinds, the overall performance was solid, with TAS showing significant growth in real-world evidence projects.
Furthermore, the company’s guidance remains largely intact, with foreign exchange improvements balancing out a more measured growth in R&DS. While there are some concerns about policy volatility affecting customer behavior, the current market conditions present an attractive entry point for patient investors. The combination of these factors, along with the company’s ability to navigate challenges and capitalize on opportunities, supports the Buy rating.

In another report released yesterday, Truist Financial also maintained a Buy rating on the stock with a $209.00 price target.